Skip to main content

Table 5 HIV, HBsAg, anti-HCV, HCV PCR prevalence and HCV viraemic rate among participants (n = 3439)

From: Hepatitis B, hepatitis C and HIV prevalence and related sexual and substance use risk practices among key populations who access HIV prevention, treatment and related services in South Africa: findings from a seven-city cross-sectional survey (2017)

  SWs (n = 1528) MSM (n = 746) PWUD/ID (n = 1165) TOTAL
  CT PE Mthatha DBN PMB CT JHB PTA CT DBN PTA  
N 384 248 248 399 249 250 250 246 367 398 400 3439
HIV + ve 69 (18%) 90 (38%) 133 (56%) 220 (55%) 199 (80%) 101 (40%) 122 (49%) 97 (41%) 22 (6%) 65 (16%) 140 (35%) 1258 (37%)
HBsAg + ve 13 (3%) 8 (3%) 10 (4%) 17 (4%) 13 (5%) 9 (4%) 10 (4%) 6 (2%) 20 (5%) 15 (4%) 20 (5%) 141 (4%)
Anti-HCV + ve ELISA 1 (< 1%) 0 0 0 0 16 (6%) 3 (1%) 1 (< 1%) 136 (37%) 113 (28%) 288 (72%) 558 (16%)
HCV viral load detectable 0 0 0 0 0 15 (6%) 2 (1%) 0 102 (28%) 90 (23%) 227 (57%) 436 (13%)
HCV viraemic rate (among anti_HCV + ve) 0 0 0 0 0 94% 67% 0 75% 80% 79% 78%
Anti-HCV-HIV co-infection 0 0 0 0 0 6 (2%) 3 (1%) 1 (< 1%) 10 (3%) 25 (6%) 113 (28%) 158 (5%)
Anti-HCV prevalence among HIV + ve participants 0 0 0 0 0 6 (6%) 3 (2%) 1 (1%) 10 (45%) 25 (38%) 113 (81%) 158 (13%)
Anti-HCV-HBV co-infection 0 0 0 0 0 1 (< 1%) 0 0 5 (1%) 5 (1%) 17 (4%) 28 (< 1%)
HIV-HBsAg co-infection 5 (1%) 3 (1%) 9 (4%) 13 (3%) 12 (5%) 5 (2%) 7 (3%) 3 (1%) 3 (1%) 6 (2%) 9 (2%) 75 (2%)
HIV-anti-HCV-HBV co-infection 0 0 0 0 0 0 0 0 0 2 (1%) 8 (2%) 10 (< 1%)
  1. CT Cape Town, DBN Durban, JHB Johannesburg, PE Port Elizabeth, PMB Pietermaritzburg, PTA Pretoria